This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hanson, J. F. Articles by Weiss, A. A. Search for Related Content PubMed PubMed Citation Articles by Hanson, J. F. Articles by Weiss, A. A.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, February 2006, p. 208-213, Vol. 13, No. 2
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.2.208-213.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Neutralizing Antibodies and Persistence of Immunity following Anthrax Vaccination

James F. Hanson, Sarah C. Taft, and Alison A. Weiss^*

Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati, 231 Albert Sabin Way, Cincinnati, Ohio 45267-0524

Received 30 November 2005/ Accepted 1 December 2005

Anthrax toxin consists of protective antigen (PA) and two toxic components, lethal factor (LF) and edema factor (EF). PA binds to mammalian cellular receptors and delivers the toxic components to the cytoplasm. PA is the primary antigenic component of the current anthrax vaccine. Immunity is due to the generation of antibodies that prevent the PA-mediated internalization of LF and EF. In this study, we characterized sera obtained from vaccinated military personnel. Anthrax vaccine is administered in a series of six injections at 0, 2, and 4 weeks and 6, 12, and 18 months, followed by annual boosters. The vaccination histories of the subjects were highly varied; many subjects had not completed the entire series, and several had not received annual boosters. We developed a simple colorimetric assay using alamarBlue dye to assess the antibody-mediated neutralization of LF-mediated toxicity to the J774A.1 murine macrophage cell line. Recently vaccinated individuals had high antibody levels and neutralizing activity. One individual who had not been boosted for 5 years had low immunoglobulin G antibody levels but a detectable neutralization activity, suggesting that this individual produced low levels of very active antibodies.

Present address: Armed Forces Institute of Pathology, Washington, DC 20306-6000.

This article has been cited by other articles:

• Abboud, N., Casadevall, A. (2008). Immunogenicity of Bacillus anthracis Protective Antigen Domains and Efficacy of Elicited Antibody Responses Depend on Host Genetic Background. CVI 15: 1115-1123 [Abstract] [Full Text]  
• Park, Y. S., Lee, J. H., Hung, C.-F., Wu, T.-C., Kim, T. W. (2008). Enhancement of Antibody Responses to Bacillus anthracis Protective Antigen Domain IV by Use of Calreticulin as a Chimeric Molecular Adjuvant. Infect. Immun. 76: 1952-1959 [Abstract] [Full Text]  
• Taft, S. C., Weiss, A. A. (2008). Neutralizing Activity of Vaccine-Induced Antibodies to Two Bacillus anthracis Toxin Components, Lethal Factor and Edema Factor. CVI 15: 71-75 [Abstract] [Full Text]